The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Development of glomerulonephritis during anti-TNF-α therapy for rheumatoid arthritis
Abstract
BACKGROUND: Treatment of rheumatoid arthritis with anti-tumour necrosis factor alpha (TNFalpha) agents may lead to autoantibody formation and flares of vasculitis, but renal complications are rare. METHODS: We report the clinical and pathologic findings in five patients with longstanding rheumatoid arthritis (duration of rheumatoid arthritis, 10-30 years; mean, 23 years) who developed new onset of glomerular disease after commencing therapy with anti-TNFalpha agents (duration of therapy, 3-30 months; median, 6 months). RESULTS: At presentation, three patients were receiving etanercept, one adalimumab and one infliximab. Two subjects presented with acute renal insufficiency, haematuria, nephrotic-range proteinuria, positive lupus serologies, and hypocomplementemia, and renal biopsies showed proliferative lupus nephritis. Two individuals presented with new onset renal insufficiency, haematuria and proteinuria, and renal biopsies showed pauci-immune necrotizing and crescentic glomerulonephritis. One of these subjects, who had anti-myeloperoxidase autoantibodies, also developed pulmonary vasculitis. The fifth patient presented with nephrotic syndrome and renal biopsy findings of membranous glomerulonephritis, associated with immune complex renal vasculitis. A pathogenic role for anti-TNFalpha therapy is suggested by the close temporal relationship with development of glomerular disease, and by the improvement in clinical and laboratory abnormalities after drug withdrawal and initiation of immunosuppressive therapy in most cases. CONCLUSIONS: Rheumatoid arthritis patients receiving anti-TNFalpha agents may develop glomerulonephritis via the induction of rheumatoid arthritis-related nephropathy or de novo autoimmune disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arnett, F. C., Edworthy, S. M., Bloch, D. A., Mcshane, D. J., Fries, J. F., Cooper, N. S., Healey, L. A., Kaplan, S. R., Liang, M. H., Luthra, H. S., et al. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310302 · Cited by 19,752
Revised Criteria for the Classification of Rheumatoid Arthritis
Arnett, F. C. (1990) · Orthopaedic Nursing · doi:10.1097/00006416-199003000-00011 · Cited by 7,723
Maini, R., St Clair, E. W., Breedveld, F., Furst, D., Kalden, J., Weisman, M., Smolen, J., Emery, P., Harriman, G., Feldmann, M., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)05246-0 · Cited by 2,345
The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited
Weening, J. J., D’Agati, V. D., Schwartz, M. M., Seshan, S. V., Alpers, C. E., Appel, G. B., Balow, J. E., Bruijn, J. A., Cook, T., Ferrario, F., et al. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000108969.21691.5d · Cited by 2,008
Self-citationCompromised Function of Regulatory T Cells in Rheumatoid Arthritis and Reversal by Anti-TNFα Therapy
Ehrenstein, M. R., Evans, J. G., Singh, A., Moore, S., Warnes, G., Isenberg, D. A., & Mauri, C. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040165 · Cited by 1,252
Drug-induced systemic lupus erythematosus associated with etanercept therapy
Shakoor, N., Michalska, M., Harris, C. A., & Block, J. A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07714-0 · Cited by 458
Aringer, M., Graninger, W. B., Steiner, G., & Smolen, J. S. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20576 · Cited by 342
Safety of Tumour Necrosis Factor-?? Antagonists
Khanna, D., McMahon, M., & Furst, D. E. (2004) · Drug Safety · doi:10.2165/00002018-200427050-00003 · Cited by 202
Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents.
Mohan, N., Edwards, E. T., Cupps, T. R., Slifman, N. R., Jong-Hoon, L., Siegel, J. N., & Braun, M. M. (2004) · PubMed · Cited by 200
Chronic therapy with recombinant tumor necrosis factor-α in autoimmune NZB/NZW F1 mice
Gordon, C., Ranges, G. E., Greenspan, J. S., & Wofsy, D. (1989) · Clinical Immunology and Immunopathology · doi:10.1016/0090-1229(89)90157-8 · Cited by 167
Cited by
Autoimmune Diseases Induced by TNF-Targeted Therapies: Analysis of 233 Cases
Ramos-Casals, M., Brito-Zerón, P., Muñoz, S., Soria, N., Galiana, D., Bertolaccini, L., Cuadrado, M.-J., & Khamashta, M. A. (2007) · Medicine · doi:10.1097/md.0b013e3181441a68 · Cited by 733
TNF receptor 2 pathway: drug target for autoimmune diseases
Faustman, D., & Davis, M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3030 · Cited by 446
Beigel, F., Schnitzler, F., Paul Laubender, R., Pfennig, S., Weidinger, M., Göke, B., Seiderer, J., Ochsenkühn, T., & Brand, S. (2011) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21362 · Cited by 84
Metadata
- Authors
- Stokes, M. B., Foster, K., Markowitz, G. S., Ebrahimi, F., Hines, W., Kaufman, D., Moore, B., Wolde, D., & D'Agati, V. D.
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-04-19
- Volume
- 20
- Issue
- 7
- Pages
- 1400-1406
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- OpenAlex
- W2125346357
- Cited by
- 266
- References
- 17
- FWCI
- 11.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Development of glomerulonephritis during anti-TNF-α therapy for rheumatoid arthritis. https://app.cochat.ai/papers/10.1093/ndt/gfh832
- The paper
- Stokes, M. B., Foster, K., Markowitz, G. S., Ebrahimi, F., Hines, W., Kaufman, D., Moore, B., Wolde, D., & D'Agati, V. D. (2005). Development of glomerulonephritis during anti-TNF-α therapy for rheumatoid arthritis. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfh832
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.